Recurrence of hepatocellular carcinoma (HCC) 10 years after liver transplantation (LT) is very rare. Here, we present two cases of peritoneal metastasis of HCC that occurred 10 and 12 years after LT. A 77-year-old male who had undergone deceased-donor LT 10 years earlier showed slow progressive elevation of tumor marker levels over 6 months. Close observation with frequent imaging studies and monthly tumor marker analyses revealed a solitary peritoneal seeding mass. Imaging studies revealed that the mass was highly likely to be metastatic HCC. After excision of the mass, all tumor markers returned to the normal range. Over past 10 months, the patient has received everolimus monotherapy and half-dose sorafenib, and has shown no evidence of HCC recurrence. In the second case, marginally elevated tumor marker levels were detected in a 65-year-old male who had undergone living-donor LT 12 years earlier.
INTRODUCTION
Liver transplantation (LT) is an established treatment for patients with liver cirrhosis and/or hepatocellular carcinoma (HCC). Patient selection according to institutional eligibility criteria contributes to reduction of HCC recurrence after LT, but a considerable number of LT recipient deaths are still associated with HCC recurrence. [1] [2] [3] [4] [5] HCC recurrence usually happens during the first a few years after LT, although very late recurrence has been reported sporadically. Because of the rarity of very late HCC recurrence that occurs at least 10 years after transplantation, 6, 7 early detection is difficult and a therapeutic strategy for such tumors has not yet been established.
Currently, there are no clear recommendations or consensuses for the management of recurrent HCC, particularly peritoneal metastasis. Here, we describe two cases of peritoneal metastasis of HCC that occurred 10 and 12 years after LT and discuss a therapeutic strategy for such patients.
CASE

Case 1
A 67-year-old male underwent deceased-donor LT for hepatitis B virus-associated liver cirrhosis and HCC ( At the age of 77 years (10 years after LT), the patient showed slow elevation of tumor marker levels during 6 months of outpatient clinic follow-ups. Because of slow but progressive elevations of the levels of AFP and protein induced by vitamin K antagonist or absence-II (PIVKA-II) (Fig. 2) , the patient was closely observed by bimonthly computed tomography (CT) analyses of the chest and abdomen-pelvis, as well as monthly tumor marker tests. After observation for 6 months, a single 2 cm-sized mass was found around the transverse colon ( Fig. 1C and 1D ). The lesion was visible on the CT scan taken 2 months previously, but we had missed it at that time ( Fig. 1C) . There was only a slight growth of the mass during the 2 month period. A positron emission tomography (PET) scan using [ 18 F]-fluorodeoxyglucose revealed that the mass showed hypermetabolic uptake (Fig.   3 ). During this work-up, serum levels of AFP and PIVKA-II were gradually elevated. These findings suggested that the mass was likely to be metastatic HCC.
Open laparotomy was performed, and the mass was excised with tumor-negative resection margins. A pathological analysis confirmed that the mass was metastatic HCC. After excision, the patient's tumor marker levels rapidly returned to normal ranges ( (Fig. 4D) . A PET scan using [ 18 F]-fluorodeoxyglucose revealed that the mass showed hypermetabolic uptake (Fig. 6 ). At this time, the AFP level was gradually elevated but was still within the normal range (Fig. 5A ). These findings suggested that the mass was likely to be metastatic HCC.
Open laparotomy was performed, and two masses were excised with equivocal tumor-negative resection margins (Fig. 7) . A pathological analysis confirmed that the masses were metastatic HCCs. After excision, the patient's AFP level dropped rapidly (Fig. 5A) ; however, 6 months later, it increased again, although it was still within the normal range. Follow-up CT and PET scans revealed multiple seeding nodules at the pelvis (Fig. 8) . The patient underwent treatment with low-dose calcineurin inhibitor, sirolimus, and full-dose sorafenib, and displayed no serious adverse side-effects. Growth of the peritoneal seeding nodules was visualized on follow-up CT scans, and sorafenib therapy was stopped after 2 years of administration.
The patient changed to receive everolimus monotherapy because its Korean National Health Insurance coverage for LT recipients. During the 6 years since HCC recurrence was diagnosed, the patient has shown very slow growing tumors, alongside elevated AFP levels ( Fig. 5B and Fig. 9 ), but has been doing well without significant deterioration of his quality of life. Recently, he has been hospitalized twice due to deterioration of his general condition. We expect that supportive care will prolong his life further.
DISCUSSION
Although the majority of HCC recurrence happens during the first a few years after LT, a small number of patients display very late recurrence, sometimes as late as 10 years after transplantation. Advanced HCC beyond the Milan criteria is often associated with early HCC recurrence; however, like the two cases described here, the is the most effective therapy for recurrent HCC in LT recipients. We previously reported a beneficial effect of surgical metastasectomy of metachronous pulmonary and adrenal metastases from HCCs on patient survival. 12, 13 There are only a small number of studies supporting resection of tumors arising from peritoneal seeding of HCC, and resection of peritoneal metastases should only be considered in patients whose primary liver neoplasm is under control and who have no metastases in other organs. [14] [15] [16] Since there was no evidence of tumor recurrence other than localized peritoneal metastasis in the two cases described here, we decided to perform peritoneal metastasectomy in both patients.
In LT recipients with HCC recurrence, metastasectomy
is not considered to be curative because it can be compat- recurrence. In the cases described here, we switched the primary immunosuppressant therapy to mTOR inhibitor after HCC recurrence and de novo malignancy; however, there is still a lack of strong evidence supporting immunosuppressive treatment regimens using mTOR inhibitors.
18-21
The multikinase inhibitor sorafenib is an effective therapy for HCC. 22, 23 Lifelong surveillance is necessary for LT recipients because HCC recurrence can occur after prolonged periods, as highlighted in the two cases described here. Since most recurrences are diagnosed subclinically, surveillance via frequent tumor marker testing is the cornerstone of follow-up studies to detect HCC recurrence in a timely manner.
In conclusion, very late peritoneal metastasis of HCC happens sporadically. We suggest that the therapeutic modality for this condition includes local control through surgical resection if possible, everolimus monotherapy, and long-term use of sorafenib.
